JLE

Hépato-Gastro & Oncologie Digestive

MENU

Les hépatites virales non-A, non-B, non-C, non-D Volume 25, numéro 1, Janvier 2018

  • [1] Blasco-Perrin H., Abravanel F., Blasco-Baque V., Péron J.M. Hepatitis E, the neglected one. Liver Int. 2016;36:130-134. Suppl. 1
  • [2] Abravanel F., Lhomme S., Dubois M. Hepatitis E virus. Med Mal Infect. 2013;43:263-270.
  • [3] Donnelly MC, Scobie L, Crossan CL, Dalton H, Hayes PC, Simpson KJ. Review article : hepatitis E-a concise review of virology, epidemiology, clinical presentation and therapy. Aliment Pharmacol Ther 2017 ; 46 : 126-41.
  • [4] Lu L., Li C., Hagedorn C.H. Phylogenetic analysis of global hepatitis E virus sequences : genetic diversity, subtypes and zoonosis. Rev Med Virol. 2006;16:5-36.
  • [5] Krawczynski K., Kamili S., Aggarwal R. Global epidemiology and medical aspects of hepatitis E. Forum (Genova). 2001;11:166-179.
  • [6] Péron J.M., Mansuy J.M., Poirson H. Hepatitis E is an autochthonous disease in industrialized countries. Analysis of 23 patients in South-West France over a 13-month period and comparison with hepatitis A. Gastroenterol Clin Biol. 2006;30:757-762.
  • [7] Renou C., Moreau X., Pariente A., ANGH, France. A national survey of acute hepatitis E in France. Aliment Pharmacol Ther. 2008;27:1086-1093.
  • [8] Mansuy J.M., Abravanel F., Miedouge M. Acute hepatitis E in south-west France over a 5-year period. J Clin Virol. 2009;44:74-77.
  • [9] Mansuy J.M., Gallian P., Dimeglio C. A nationwide survey of hepatitis E viral infection in French blood donors. Hepatology. 2016;63:1145-1154.
  • [10] Gallian P., Lhomme S., Piquet Y. Hepatitis E virus infections in blood donors, France. Emerg Infect Dis. 2014;20:1914-1917.
  • [11] Péron JM, Dalton H, Izopet J, Kamar N. Acute autochthonous hepatitis E in western patients with underlying chronic liver disease : a role for ribavirin? J Hepatol 2011 ; 5 : 1323-4 ; author reply 1324-5.
  • [12] Kamar N., Bendall R.P., Peron J.M. Hepatitis E virus and neurologic disorders. Emerg Infect Dis. 2011;17:173-179.
  • [13] Kamar N, Selves J, Mansuy JM, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med 2008 ; 358 : 811-7.
  • [14] Kamar N, Izopet J, Tripon S, et al. Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med 2014 ; 370 : 1111-20.
  • [15] Mallet V., Nicand E., Sultanik P. Brief communication : case reports of ribavirin treatment for chronic hepatitis E. Ann Intern Med. 2010;153:85-89.
  • [16] Shrestha M.P., Scott R.M., Joshi D.M. Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med. 2007;356:895-903.
  • [17] Zhu F.C., Zhang J., Zhang X.F. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults : a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet. 2010;376:895-902.
  • [18] Dochez V, Ducarme G. Acute herpesviridae hepatitis during pregnancy: A review. Presse Med 2015 ; 44 (6 Pt 1) : 660-6.
  • [19] Ichai P., Roque Afonso A.M., Sebagh M. Herpes simplex virus-associated acute liver failure : a difficult diagnosis with a poor prognosis. Liver Transpl. 2005;11:1550-1555.
  • [20] Moldovan B, Mentha G, Majno P, et al. Demographics and outcomes of severe herpes simplex virus hepatitis : a registry-based study. J Hepatol 2011 ; 55 : 1222-6.
  • [21] Riediger C., Sauer P., Matevossian E., Müller M.W., Büchler P., Friess H. Herpes simplex virus sepsis and acute liver failure. Clin Transplant. 2009;23:37-41. Suppl. 21
  • [22] Pishvaian A.C., Bahrain M., Lewis J.H. Fatal varicella-zoster hepatitis presenting with severe abdominal pain : a case report and review of the literature. Dig Dis Sci. 2006;51:1221-1225.
  • [23] Alvite-Canosa M., Paniagua-Martín M.J., Quintela-Fandiño J., Otero A., Crespo-Leiro M.G. Fulminant hepatic failure due to varicella zoster in a heart transplant patient : successful liver transplant. J Heart Lung Transplant. 2009;28:1215-1216.
  • [24] Meriglier E., Coudroy R., Agius G. Fatal fulminant varicella-zoster virus hepatitis in a female patient with Crohn's disease treated by an anti-TNF-alpha agent. Med Mal Infect. 2014;44:484-486.
  • [25] Seehofer D, Rayes N, Tullius SG, et al. CMV hepatitis after liver transplantation : incidence, clinical course, and long-term follow-up. Liver Transpl 2002 ; 8 : 1138-46.
  • [26] Åsberg A., Humar A., Rollag H. Lessons learned from a randomized study of oral valganciclovir versus parenteral ganciclovir treatment of cytomegalovirus disease in solid organ transplant recipients : The VICTOR trial. Clin Infect Dis. 2016;62:1154-1160.
  • [27] Hinedi T.B., Koff R.S. Cholestatic hepatitis induced by Epstein-Barr virus infection in an adult. Dig Dis Sci. 2003;48:539-541.
  • [28] Drebber U, Kasper HU, Krupacz J, et al. The role of Epstein-Barr virus in acute and chronic hepatitis. J Hepatol 2006 ; 44 : 879-85.
  • [29] Mellinger J.L., Rossaro L., Naugler W.E. Epstein-Barr virus (EBV) related acute liver failure : a case series from the US Acute Liver Failure Study Group. Dig Dis Sci. 2014;59:1630-1637.
  • [30] Phan TL, Lautenschlager I, Razonable RR, Munoz FM. HHV-6 in liver transplantation : A literature review. Liver Int. 2017 Jun 26. doi: 10.1111/liv.13506 [Epub ahead of print].
  • [31] Harma M., Hockerstedt K., Lautenschlager I. Human herpesvirus-6 and acute liver failure. Transplantation. 2003;76:536-539.
  • [32] Buyse S., Roque-Afonso A.M., Vaghefi P. Acute hepatitis with periportal confluent necrosis associated with human herpesvirus 6 infection in liver transplant patients. Am J Clin Pathol. 2013;140:403-409.
  • [33] Riva G., Luppi M., Barozzi P., Forghieri F., Potenza L. How I treat HHV8/KSHV-related diseases in posttransplant patients. Blood. 2012;120:4150-4159.
  • [34] Caseris M., Burdet C., Lepeule R. An update on measles. Rev Med Interne. 2015;36:339-345.
  • [35] Moss WJ, Griffin DE. Measles. Lancet 2012 ; 379 : 153-64.
  • [36] Bihari C, Rastogi A, Saxena P, et al. Parvovirus b19 associated hepatitis. Hepat Res Treat 2013. 2013: p. 472027.
  • [37] Ronan B.A., Agrwal N., Carey E.J. Fulminant hepatitis due to human adenovirus. Infection. 2014;42:105-111.
  • [38] Wang S.M., Liu C.C., Yang Y.J., Yang H.B., Lin C.H., Wang J.R. Fatal coxsackievirus B infection in early infancy characterized by fulminant hepatitis. J Infect. 1998;37:270-273.
  • [39] Chan R.C., Penney D.J., Little D., Carter I.W., Roberts J.A., Rawlinson W.D. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet. 2001;358:121-122.
  • [40] Back AT, Lundkvist A. Dengue viruses - an overview. Infect Ecol Epidemiol 2013 ; Aug 30. 3. doi: 10.3402/iee.v3i0.19839.
  • [41] Madani T.A., Al-Mazrou Y.Y., Al-Jeffri M.H. Rift Valley fever epidemic in Saudi Arabia : epidemiological, clinical, and laboratory characteristics. Clin Infect Dis. 2003;37:1084-1092.
  • [42] Akinci E., Bodur H., Sunbul M., Leblebicioglu H. Prognostic factors, pathophysiology and novel biomarkers in Crimean-Congo hemorrhagic fever. Antiviral Res. 2016;132:233-243.
  • [43] Marroquin JLH, Richards GA, Jiménez JIS, Baker T, Amin P. Viral hemorrhagic fever in the tropics : Report from the task force on tropical diseases by the World Federation of Societies of Intensive and Critical Care Medicine. J Crit Care 2017. Nov 4. pii : S0883-9441(17)31713-6. doi : 10.1016/j.jcrc.2017.11.006.
  • [44] Campbell GL1, Marfin A.A., Lanciotti R.S., Gubler D.J. West Nile virus. Lancet Infect Dis. 2002;2:519-529.
  • [45] Thiberville S.D., Moyen N., Dupuis-Maguiraga L. Chikungunya fever : epidemiology, clinical syndrome, pathogenesis and therapy. Antiviral Res. 2013;99:345-370.